Neoantigen-based personalized immunotherapy
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Neoantigen-based personalized immunotherapy, covering 2026-03-31 to 2026-03-31. Get the full timeline:
Most recent: Clinical Trial Update: Safety and Efficacy of Neoantigen-Based Personalized Immunotherapy as Consolidation Therapy After Standard Adjuvant Treatment in Resectable Stage III Colorectal Cancer or Non-Small Cell Lung Cancer [Phase 1]